Discovery and Development of Second-Generation Proteasome Inhibitors

Seminars in Hematology

Volumn 49, Issue 3, 2012, Pages 207-214

  Kirk, Christopher J ^a  

^a ONYX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTONE; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; DELANZOMIB; DEXAMETHASONE; EPOXYKETONE; FLUOROURACIL; IXAZOMIB; IXAZOMIB CITRATE; LENALIDOMIDE; MELPHALAN; ONX 0914; OPROZOMIB; OXOPLATIN; PR 047; PR 924; PR 957; PROTEASOME; PROTEASOME INHIBITOR; SALINOSPORAMIDE A; THALIDOMIDE; UNCLASSIFIED DRUG; VORINOSTAT;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; COLORECTAL CARCINOMA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVE SITE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; MULTIPLE MYELOMA; MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR CELL; UNFOLDED PROTEIN RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANIMALS; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PYRAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862689569     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.04.007     Document Type: Article

References (72)

1. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005, 6:79-87.
2. Goldberg A.L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 2007, 35:12-17.
3. Orlowski R.Z., Voorhees P.M., Garcia R.A., et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105:3058-3065.
4. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
5. Orlowski R.Z., Kuhn D.J. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008, 14:1649-1657.
6. Navon A., Ciechanover A. The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 2009, 284:33713-33718.
7. Borissenko L., Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007, 107:687-717.
8. Kloetzel P.M., Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004, 16:76-81.
9. Griffin T.A., Nandi D., Cruz M., et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 1998, 187:97-104.
10. Kloetzel P.M. Antigen processing by the proteasome. Nat Rev Mol Cell Biol 2001, 2:179-187.
11. Dick L.R., Fleming P.E. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010, 15:243-249.
12. Kupperman E., Lee E.C., Cao Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010, 70:1970-1980.
13. Piva R., Ruggeri B., Williams M., et al. CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 2008, 111:2765-2775.
14. Dorsey B.D., Iqbal M., Chatterjee S., et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. J Med Chem 2008, 51:1068-1072.
15. Sanchez E., Li M., Steinberg J.A., et al. The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan. Br J Haematol 2010, 148:569-581.
16. Chauhan D., Tian Z., Zhou B., et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011, 17:5311-5321.
17. Bringhen S., Larocca A., Rossi D., et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010, 116:4745-4753.
18. Richardson P.G., Baz R., Wang L., et al. Investigational agent MLN9708, an oral proteasome inhibitor, in patients (Pts) with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study. ASH Annual Meeting Abstracts 2011, 118:301.
19. Kumar S., Bensinger W.I., Reeder C.B., et al. weekly dosing of the investigational oral proteasome inhibitor MLN9708 in patients with relapsed and/or refractory multiple myeloma: results from a phase 1 dose-escalation study. ASH Annual Meeting Abstracts 2011, 118:816.
20. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
21. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121.
22. Demo S.D., Kirk C.J., Aujay M.A., et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 2007, 67:6383-6391.
23. Groll M., Kim K.B., Kairies N., Huber R., Crews C.M. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of a' b' - epoxyketone proteasome inhibitors. J Am Chem Soc 2003, 122:1237-1238.
24. Mirabella A.C., Pletnev A.A., Downey S.L., et al. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol 2011, 18:608-618.
25. Kuhn D.J., Chen Q., Voorhees P.M., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
26. Dasmahapatra G., Lembersky D., Kramer L., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115:4478-4487.
27. Zhou H.J., Aujay M.A., Bennett M.K., et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009, 52:3028-3038.
28. Sacco A., Aujay M., Morgan B., et al. Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's macroglobulinemia. Clin Cancer Res 2011, 17:1753-1764.
29. Chauhan D., Singh A.V., Aujay M., et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 2010, 116:4906-4915.
30. Roccaro A.M., Sacco A., Aujay M., et al. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood 2010, 115:4051-4060.
31. Muchamuel T., Basler M., Aujay M.A., et al. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 2009, 15:781-787.
32. Parlati F., Lee S.J., Aujay M., et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114:3439-3447.
33. Singh A.V., Bandi M., Aujay M.A., et al. PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol 2011, 152:155-163.
34. O'Connor O.A., Stewart A.K., Vallone M., et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009, 15:7085-7091.
35. Alsina M., Trudel S., Vallone M., Molineaux C., Kunkel L., Goy A. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. ASH Annual Meeting Abstracts 2007, 110:411.
36. Siegel D.S., Martin T., Wang M., et al. Results of PX-171-003-A1, an open-label, single-arm, phase 2 (Ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 2010, 116:985.
37. Vij R., Kaufman J.L., Jakubowiak A.J., et al. Final results from the bortezomib-naive group of PX-171-004, a phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory MM. ASH Annual Meeting Abstracts 2011, 118:813.
38. Papadopoulos K.P., Mendelson D.S., Tolcher A.W., et al. A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors. ASCO Meeting Abstracts 2011, 29:3075.
39. Groll M., Huber R., Potts B.C. Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. J Am Chem Soc 2006, 128:5136-5141.
40. Chauhan D., Catley L., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8:407-419.
41. Chauhan D., Singh A.V., Ciccarelli B., Richardson P.G., Palladino M.A., Anderson K.C. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2010, 115:834-845.
42. Cusack J.C., Liu R., Xia L., et al. NPI-0052 enhances tumoricidal response to conventional cancer therapy in a colon cancer model. Clin Cancer Res 2006, 12:6758-6764.
43. Miller C.P., Rudra S., Keating M.J., Wierda W.G., Palladino M., Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood 2009, 113:4289-4299.
44. Hofmeister C.C., Richardson P., Zimmerman T., et al. Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM). ASCO Meeting Abstracts 2009, 27:8505.
45. Richardson P.G., Spencer A., Cannell P., et al. Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed/refractory multiple myeloma (MM). ASH Annual Meeting Abstracts 2011, 118:302.
46. Millward M., Price T., Townsend A., et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs Nov 2011, Epub ahead of print.
47. Britton M., Lucas M.M., Downey S.L., et al. Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like situes. Chem Biol 2009, 16:1278-1289.
48. Mirabella A.C., Pletnev A.A., Downey S.L., et al. Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol 2011, 18:608-618.
49. Arastu-Kapur S., Anderl J.L., Kraus M., et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res 2011, 17:2734-2743.
50. Papadopoulos K., Capua Siegel D.S., Singhal S.B., et al. Phase 1b evaluation of the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory multiple myeloma. ASH Annual Meeting Abstracts 2010, 116:3024.
51. Miller C.P., Manton C.A., Hale R., et al. Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs. Chem Biol Interact 2011, 194:58-68.
52. Bross P.F., Kane R., Farrell A.T., et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin Cancer Res 2004, 10:3954-3964.
53. Lonial S., Waller E.K., Richardson P.G., et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106:3777-3784.
54. Kirk C.J., Jiang J., Muchamuel T., et al. The selective proteasome inhibitor carfilzomib is well tolerated in experimental animals with dose intensive administration. ASH Annual Meeting Abstracts 2008, 112:2765.
55. Cavaletti G., Jakubowiak A.J. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma 2010, 51:1178-1187.
56. Corso A., Mangiacavalli S., Varettoni M., et al. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients. Leuk Res 2010, 34:471-474.
57. Richardson P.G., Briemberg H., Jagannath S., et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
58. Cavaletti G., Gilardini A., Canta A., et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007, 204:317-325.
59. Chao J.R., Parganas E., Boyd K., Hong C.Y., Opferman J.T., Ihle J.N. Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons. Nature 2008, 452:98-102.
60. Martins L.M., Morrison A., Klupsch K., et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004, 24:9848-9862.
61. Singhal S., Siegel D.S., Martin T., et al. Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. ASH Annual Meeting Abstracts 2011, 118:1876.
62. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
63. Hideshima T., Ikeda H., Chauhan D., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
64. Walter P., Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011, 334:1081-1086.
65. Chapman M.A., Lawrence M.S., Keats J.J., et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011, 471:467-472.
66. Fernandez Y., Verhaegen M., Miller T.P., et al. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 2005, 65:6294-6304.
67. Qin J.Z., Ziffra J., Stennett L., et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 2005, 65:6282-6293.
68. Dasmahapatra G., Lembersky D., Son M.P., et al. Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther 2011, 10:1686-1697.
69. Garrett I.R., Chen D., Gutierrez G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003, 111:1771-1782.
70. Zangari M., Esseltine D., Lee C.K., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005, 131:71-73.
71. Zangari M., Aujay M., Zhan F., et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol 2011, 86:484-487.
72. Groettrup M., Kirk C.J., Basler M. Proteasomes in immune cells: more than peptide producers?. Nat Rev Immunol 2010, 10:73-78.